Falk G Bechara, Angelo V Marzano, Antonio Martorell, Hessel H van der Zee, Valeria Jordan M, Nicolas Thomas, Ivette Alarcon, Axel P Villani, Christos C Zouboulis, John R Ingram
{"title":"Towards a Paradigm Shift in Delivering Hidradenitis Suppurativa Care: a Narrative Review.","authors":"Falk G Bechara, Angelo V Marzano, Antonio Martorell, Hessel H van der Zee, Valeria Jordan M, Nicolas Thomas, Ivette Alarcon, Axel P Villani, Christos C Zouboulis, John R Ingram","doi":"10.1007/s13555-025-01462-7","DOIUrl":null,"url":null,"abstract":"<p><p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder characterized by deep-seated nodules, recurrent painful abscesses, and draining tunnels in the intertriginous skin areas that may lead to irreversible tissue damage and scarring. This disfiguring and debilitating disease is also associated with several systemic comorbid disorders, mental health issues, and reduced quality of life. Recent research has significantly advanced our understanding of HS pathogenesis, thereby opening doors to novel treatments. However, challenges persist, such as disease underreporting, diagnostic delays, and a scarcity of evidence-based treatments. Owing to diagnostic delays, the therapeutic \"window of opportunity\" is often missed, contributing to suboptimal outcomes, with the patient receiving treatment only at advanced stages of the disease. The heterogeneity in outcome measures and the relative lack of well-defined disease phenotypes and biomarkers further complicates the management of the disease. Strategies aimed toward early treatment initiation, identifying patient phenotypes or risk factors for rapid disease progression, and timely intervention with biologic therapy could enhance treatment outcomes. This article presents a review of these critical areas and the potential measures that could improve patient care leading to a better quality of life.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01462-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder characterized by deep-seated nodules, recurrent painful abscesses, and draining tunnels in the intertriginous skin areas that may lead to irreversible tissue damage and scarring. This disfiguring and debilitating disease is also associated with several systemic comorbid disorders, mental health issues, and reduced quality of life. Recent research has significantly advanced our understanding of HS pathogenesis, thereby opening doors to novel treatments. However, challenges persist, such as disease underreporting, diagnostic delays, and a scarcity of evidence-based treatments. Owing to diagnostic delays, the therapeutic "window of opportunity" is often missed, contributing to suboptimal outcomes, with the patient receiving treatment only at advanced stages of the disease. The heterogeneity in outcome measures and the relative lack of well-defined disease phenotypes and biomarkers further complicates the management of the disease. Strategies aimed toward early treatment initiation, identifying patient phenotypes or risk factors for rapid disease progression, and timely intervention with biologic therapy could enhance treatment outcomes. This article presents a review of these critical areas and the potential measures that could improve patient care leading to a better quality of life.
期刊介绍：
Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers.
The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
